(Q40485092)

20 September 2017

title

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors (English)

1 reference

20 September 2017

Anthony W Tolcher

1

1 reference

20 September 2017

Patricia LoRusso

2

1 reference

20 September 2017

Jennifer Arzt

3

1 reference

20 September 2017

Todd A Busman

4

1 reference

20 September 2017

Guinan Lian

5

1 reference

20 September 2017

Niki S Rudersdorf

6

1 reference

20 September 2017

Carol Ann Vanderwal

7

1 reference

20 September 2017

Whitney Kirschbrown

8

1 reference

20 September 2017

Kyle D Holen

9

1 reference

20 September 2017

Lee S Rosen

10

1 reference

20 September 2017

publication date

29 September 2015

1 reference

Cancer Chemotherapy and Pharmacology

20 September 2017

published in

1 reference

20 September 2017

volume

76

1 reference

20 September 2017

issue

5

1 reference

20 September 2017

page(s)

1025-1032

1 reference

Dysregulation of apoptosis genes in hematopoietic malignancies.

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2883-8

10.1007/S00280-015-2883-8

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

1012512633

0 references

1 reference